10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Everolimus-based therapy and endocrine monotherapy are used among postmenopausal women with hormone receptor-positive human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) whose disease progressed or recurred on a non-steroidal aromatase inhibitor (NSAI). However, limited evidence exists regarding the real-world comparative effectiveness of these agents.

          Related collections

          Author and article information

          Journal
          Curr Med Res Opin
          Current medical research and opinion
          Informa Healthcare
          1473-4877
          0300-7995
          Jun 2015
          : 31
          : 6
          Affiliations
          [1 ] Analysis Group Inc. , New York, NY , USA.
          Article
          10.1185/03007995.2015.1021906
          25971725
          d2de8d6c-98ac-454b-b913-5c0a805c2585
          History

          Breast cancer,Clinical outcomes,Endocrine therapy,Everolimus,HR+/HER2− metastatic breast cancer

          Comments

          Comment on this article